Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure

Objective: To study whether the effect of allopurinol on improvement of endothelial dysfunction in chronic heart failure (CHF) translates into improved exercise capacity and to examine whether allopurinol also improves B-type natriuretic peptide (BNP), the other important prognostic marker of CHF. Design: Randomised, double blind, placebo controlled crossover trial. Setting: Teaching hospital. Patients: 50 patients with CHF (New York Heart Association functional classes II and III) were recruited. Interventions: 50 patients with CHF were randomly assigned to three months’ treatment with allopurinol (300 mg/day) or placebo. At two and three months into treatment, they underwent a modified Bruce exercise protocol and a six minute walk test. Blood was taken for BNP and haemoglobin analysis. Results: Neither exercise test was altered by allopurinol. However, plasma BNP concentrations fell significantly (p  =  0.035) with allopurinol (11.9 pmol/l) versus placebo (14.4 pmol/l). Haemoglobin concentrations also fell highly significantly with allopurinol (p  =  0.001). Conclusions: An important negative finding is that despite high hopes for it, allopurinol had no effect on exercise capacity in CHF. On the other hand, allopurinol did reduce BNP, which is the best available surrogate marker for prognosis in CHF.

[1]  J. Rouleau,et al.  Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.

[2]  D. Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .

[3]  J. Cohn,et al.  The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. , 2004, European heart journal.

[4]  L. Tomasoni,et al.  Drugs Modifying Nitric Oxide Metabolism Affect Plasma Cholesterol Levels, Coagulation Parameters, Blood Pressure Values and the Appearance of Plasma Myocardial Necrosis Markers in Rabbits: Opposite Effects of L-NAME and Nitroglycerine , 2004, Cardiovascular Drugs and Therapy.

[5]  J. Keaney,et al.  The clinical implications of endothelial dysfunction. , 2003, Journal of the American College of Cardiology.

[6]  M. Hori,et al.  Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy , 2003, Circulation.

[7]  L. Tavazzi,et al.  Antiremodeling Effect of Long-Term Exercise Training in Patients With Stable Chronic Heart Failure: Results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial , 2003, Circulation.

[8]  J. Liao,et al.  NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. , 2003, Journal of molecular and cellular cardiology.

[9]  Michael T. Watkins,et al.  Predictive value of noninvasivelydetermined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease , 2003 .

[10]  H. Katus,et al.  Acute Reduction of Myocardial Infarct Size By a Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Is Mediated by Endothelial Nitric Oxide Synthase , 2003, Journal of cardiovascular pharmacology.

[11]  W. Haynes,et al.  Xanthine Oxidase Inhibition Reverses Endothelial Dysfunction in Heavy Smokers , 2003, Circulation.

[12]  M. Watkins,et al.  Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. , 2003, Journal of the American College of Cardiology.

[13]  B. Dahlof,et al.  Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol☆ , 2002 .

[14]  F. Coppi,et al.  Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. , 2002, Journal of the American College of Cardiology.

[15]  J. Keaney,et al.  Endothelial function: a barometer for cardiovascular risk? , 2002, Circulation.

[16]  A. Richards,et al.  Plasma brain natriuretic peptide after long‐term treatment for heart failure in general practice , 2002, European journal of heart failure.

[17]  A. Takeshita,et al.  Probucol Attenuates Left Ventricular Dysfunction and Remodeling in Tachycardia-Induced Heart Failure: Roles of Oxidative Stress and Inflammation , 2002, Circulation.

[18]  A. Struthers,et al.  Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure , 2002, Circulation.

[19]  H. Drexler,et al.  Allopurinol and endothelial function in heart failure: future or fantasy? , 2002, Circulation.

[20]  Rainer Hambrecht,et al.  Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies , 2002, Circulation.

[21]  M. Watkins,et al.  Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study , 2002, Circulation.

[22]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[23]  P. Donnan,et al.  Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study , 2002, Heart.

[24]  Hiroyuki Tsutsui,et al.  Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.

[25]  T. Meinertz,et al.  Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease , 2001, Circulation.

[26]  K. Node,et al.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. , 2001, The Journal of clinical investigation.

[27]  D. Kass,et al.  Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.

[28]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[29]  R. de Caterina,et al.  Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. , 2001, Cardiovascular research.

[30]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[31]  A. D. Cunningham,et al.  Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population , 2001, Heart.

[32]  F. Perticone,et al.  Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients , 2001, Circulation.

[33]  G. Newton,et al.  Vitamin C Augments the Inotropic Response to Dobutamine in Humans With Normal Left Ventricular Function , 2001, Circulation.

[34]  Hiroyuki Tsutsui,et al.  Treatment With Dimethylthiourea Prevents Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction in Mice: Role of Oxidative Stress , 2000, Circulation research.

[35]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[36]  G D Lowe,et al.  Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. , 2000, European heart journal.

[37]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[38]  A. Morris,et al.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. , 2000, Hypertension.

[39]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[40]  D. Green,et al.  NITRIC OXIDE‐DEPENDENT ENDOTHELIAL FUNCTION IS UNAFFECTED BY ALLOPURINOL IN HYPERCHOLESTEROLAEMIC SUBJECTS , 1999, Clinical and experimental pharmacology & physiology.

[41]  HelmutDrexler.  Endothelium as a Therapeutic Target in Heart Failure , 1998 .

[42]  G. Schuler,et al.  Exercise Capacity in Patients With Chronic Heart Failure Regular Physical Exercise Corrects Endothelial Dysfunction and Improves , 1998 .

[43]  C. Pepine.  Clinical implications of endothelial dysfunction , 1998, Clinical cardiology.

[44]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[45]  A. Quyyumi,et al.  Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. , 1997, Hypertension.

[46]  K. Swedberg,et al.  What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. , 1996, European heart journal.

[47]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.